PharmaShots

FEBRUARY 17, 2023

Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)

FDA 40

FDA Vaccines 40

PharmaShots

JUNE 23, 2023

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)

FDA 40

FDA 40

PharmaShots

JUNE 16, 2023

Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B

FDA 40

FDA Labelling 40

PharmaShots

JUNE 9, 2023

Quell Therapeutics Signed an Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies Date: June 09, 2023 | Tags: Quell Therapeutics, AstraZeneca, Engineered Treg Cell Therapies, Type 1 Diabetes, Inflammatory Bowel Disease, Biotech, Treg cell engineering modules Astellas and the (..)

FDA 40

FDA 40

PharmaShots

MAY 26, 2023

Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer Date: May 26, 2023 | Tags: Takeda, HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, Regulatory, Priority Review, US, FDA Gilead Receives EMA’s CHMP Positive Opinion to Extend the Use of Veklury (remdesivir) for COVID-19 Date: (..)

FDA 40

FDA 40

PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

FDA 40

FDA Chemotherapy Immunization Hospitals 40

PharmaShots

APRIL 21, 2023

Oblato Reports the First Patient Enrolment of OKN-007 in the P-I Clinical Trial for Recurrent High-Grade Glioma Date: Apr 21, 2023 | Tags: Oblato, OKN-007, Recurrent High-Grade Glioma, Regulatory, Henry Ford Health System CARsgen's CT041 Receives the US FDA’s IND Clearance for the Postoperative Adjuvant Therapy of Pancreatic Cancer Date: (..)

FDA 40

FDA Labelling 40

PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

FDA 40

FDA 40

PharmaShots

MARCH 31, 2023

PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer Date: Mar 31, 2023 | Tags: PDS Biotech, PDS0101, Keytruda, pembrolizumab, Head, Neck Cancer, Clinical Trial, P-III, VERSATILE-003 Trial Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular (..)

FDA 40

FDA 40

Pharmaceutical Technology

SEPTEMBER 30, 2022

Skysona is indicated as a one-time gene therapy to slow the progression of cerebral adrenoleukodystrophy (CALD), a rare paediatric neurodegenerative disease in boys aged 4–17 years diagnosed with early-stage CALD. These approvals represent crucial milestones for bluebird bio, the gene therapy field, and patients with rare genetic diseases.

FDA 115

FDA Insurance 115

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

pharmaphorum

NOVEMBER 19, 2021

It is recommended as a treatment for people aged two months and older with types 1, 2 and 3 SMA, as well as some people with the condition before they start showing symptoms. million price tag make it is the most expensive treatment ever approved for NHS funding.

92

92

pharmaphorum

JUNE 12, 2022

Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8 Haematopoietic stem cell transplantation (HSCT) offers a chance of a cure, but is only possible when a donor with a matching human leukocyte antigen (HLA) signature, within the correct age range, is available.

FDA 57

FDA 57

pharmaphorum

APRIL 14, 2022

million price tag. Patients with the most severe form of inherited disorder develop life-threatening anaemia from the age of around four to six months and have to undergo monthly blood transfusions as well as additional treatment to prevent complications, such as chelation drugs to remove excess iron from the body.

FDA 62

FDA 62

Pharmaceutical Technology

DECEMBER 5, 2022

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. This is closely followed by CB2 receptors in second place. This is followed by epilepsy at 8% of the pipeline and multiple sclerosis at 7% of the pipeline.

Controlled Substances 98

Controlled Substances Compounding Immunization 98

pharmaphorum

NOVEMBER 19, 2020

Lucentis (ranibizumab) was first FDA approved in 2006 for wet age-related macular degeneration (wet AMD) and has picked up approvals in related eye conditions ever since, although its patent expired in June.

FDA 62

FDA Labelling 62

pharmaphorum

SEPTEMBER 15, 2020

“Digitally native brands are typically agile businesses from the ground up, and agility and flexibility are part of their core makeup,” says Joe Holmes, vice president, marketing services, US at Tag. Jeremy Richter, Tag. Joe began his life at Tag in the UK, bringing efficiencies to his clients, working across all conceivable channels.

Communication 106

Communication Documentation Labelling Vaccines 106

pharmaphorum

JANUARY 21, 2022

Balancing the incentivisation of innovation against affordable access to revolutionary new medicines is an age-old conundrum in the biopharmaceutical industry. In recent years, revolutionary medicines have come with price tags to match, but this is simply a symptom of our current model.

Insurance 52

Insurance Vaccines 52

PharmD Live

JANUARY 25, 2022

A PharmD dedicated to knowing approved medications and understanding the medical situations in which they are applied is critical to caring for and reducing risk to the aged and vulnerable Medicare patient population. The aging population sees more specialists. 88% report that their EHR produces clinical benefits for the practice.

Adverse Reactions 52

Adverse Reactions Patient Care Communication Hospitals 52

pharmaphorum

JUNE 2, 2021

It added that there is evidence that Evrysdi is a life-extending treatment for SMA type 1, the most serious from of the disease that generally leads to death before the age of 2 if untreated, and as an oral drug is an alternative for people who cannot have the other SMA treatment options.

Documentation 52

Documentation Communication 52

PharmD Live

DECEMBER 21, 2021

With an annual price per patient of nearly $56,000 per year, patients’ families are looking for solutions for their loved ones–with a huge price tag. For people with diabetes, the ADA makes new recommendations and strategies for classes of care, age and type, strategies to prevent or delay onset of T2 diabetes. See it here.

FDA 52

FDA Hospitals 52

The Checkup by Singlecare

JANUARY 25, 2023

RELATED: Skin cancer statistics Key findings Here are the more notable findings from our survey of 1,300 adults aged 18 and older, with a range of educational, ethnic, relationship, and income statuses. Those in the 18-24 age group were the least likely to have seen a dermatologist, with 57% never having seen a dermatologist.

Documentation 52

Documentation Insurance FDA 52

Druggist

OCTOBER 25, 2020

Virasoothe Cooling Gel can be used in toddlers and children from 6 months of age. Despite its higher price tag as compared with other products sold for the management of chickenpox PoxClin Cool Mousse is regarded as ‘highly-rated’ and well-priced product on Amazon.co.uk Buy on Amazon Price incl. Buy on Amazon Price incl.

52

52

Colors Make me Happy

AUGUST 19, 2020

For example, Fatima, along with tens of thousands of Kurdish refugees, were assigned the same birthdate (July 1) regardless of their real day of birth, which naturally causes issues in determining a patient’s actual age. Or call multiple pharmacies to make sure they have the generic version of the drug they need in the cheapest price tag.

Compounding 40

Compounding Communication 40

pharmaphorum

AUGUST 28, 2020

But the advent of COVID-19 is proving to be something of a coming of age for digital epidemiology, which has been putting data from disparate sources to global use for the last 15 years. We are ingesting hundreds of thousands of pieces of information daily and we tag that information across locations, disease types, species, and case counts.

Hospitals 63

Hospitals 63

The Checkup by Singlecare

JANUARY 23, 2024

Benign skin growths Skin growths such as moles, skin tags, and seborrheic keratosis can appear as bumps on the head. An individual’s overall health condition, age, and the severity of the head bump can all influence how long a bump on the head will last. Bone spurs : Bone spurs don’t typically go away unless they’re surgically removed.

52

52

PharmaShots

MARCH 10, 2023

Vertex Receives the US FDA’s IND Clearance of VX-264 for the Treatment of Type 1 Diabetes Date: Mar 10, 2023 | Tags: Vertex, VX-264, Type 1 Diabetes, Regulatory, US, FDA, IND Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies Date: Mar 10, 2023 | Tags: Alnylam, Medison Pharma, RNAi Therapies, Onpattro, patisiran, (..)

FDA 40

FDA Vaccines 40

The Checkup by Singlecare

MARCH 21, 2023

Belbuca is a good alternative to opioid treatment that needs to be taken around the clock, but it may come with a hefty price tag. The buccal film has a delayed peak concentration of a couple of hours to achieve the pain control effect and provides a relatively long duration of action. RELATED: Belbuca side effects 2.

Dosage 52

Dosage Controlled Substances Labelling Packaging 52

The FDA Law Blog

JUNE 27, 2023

The honor was bestowed on only 183 attorneys, which is awarded to “top attorneys under 40 whose legal accomplishments belie their age.” In addition to Mr. Karst, ten other HP&M Directors were tagged as “Recommended” by WWL: Life Sciences 2023: Ricardo Carvajal Robert A. Valentine , as a 2023 Rising Star. Dormer Jeffrey N.

FDA 81

FDA 81

pharmaphorum

AUGUST 10, 2020

While this is not cheap by anybody’s reckoning, Roche hopes that the less intimidating price tag, plus the patient-friendly oral administration method will give it a competitive edge. The FDA approved Evrysdi for the treatment of spinal muscular atrophy (SMA) in adults and children two months of age and older.

FDA 57

FDA Specialty Pharmacies 57

pharmaphorum

FEBRUARY 16, 2021

But haematopoietic stem cell transplantation is only possible when a donor with a matching human leukocyte antigen signature, within the correct age range, is available. million in Europe. NICE said that data came from a small sample of patients and is using its standard discount rate of 3.5%

66

66

The Checkup by Singlecare

JUNE 21, 2023

The endocrine disorder affects up to 10% of women of reproductive age, 40%-80% of whom have obesity. The condition causes higher levels of androgen hormone production, resulting in symptoms such as irregular menstrual cycles, acne, excess hair growth, cysts, skin tags, thinning hair, skin darkening, and infertility.

Insurance 98

Insurance FDA Compounding Compounding Pharmacies 98

pharmaphorum

DECEMBER 7, 2021

That finding could provide some comfort to Biogen and Eisai, whose recently-approved amyloid-targeting drug Aduhelm (aducanumab) is struggling to gain traction in the market on the back of unconvincing efficacy data, safety concerns and a high price tag.

Compounding 52

Compounding Insurance FDA 52

The Checkup by Singlecare

JANUARY 19, 2023

There may also be skin tags in these areas. Diabetes People with diabetes have a fasting blood sugar of 126 mg/dl or more. It is important to recognize the symptoms of high blood sugar (such as increased thirst and urination), as well as test your blood sugar, and know what to do if your blood sugar is high.

Immunization 105

Immunization Hospitals Communication 105

The Checkup by Singlecare

MAY 8, 2023

Belbuca is a good alternative to opioid treatment that needs to be taken around the clock, but it may come with a hefty price tag. The buccal film has a delayed peak concentration of a couple of hours to achieve the pain control effect, and provides a relatively long duration of action. fibromyalgia ).

Controlled Substances 52

Controlled Substances Dosage Labelling FDA 52

European Pharmaceutical Review

DECEMBER 27, 2023

Other examples include the absence of age requirement/limitation for CAR T-cell therapy and that chemo sensitivity is not mandatory for CAR treatment. This is in addition to its considerable price tag. 6-8 Clinical recommendations also change. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. 2013;368(16):1509–18.

Adverse Reactions 85

Adverse Reactions Immunization Medical Schools Chemotherapy 85